Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
RESEARCH TOOLSreports
Top Page
ArriVent BioPharma, Inc.
(NASDAQ:AVBP)
Rating:39Underperform
Price Target:―
Positive Factors
Management
ArriVent's management team is experienced, with the CEO having a successful track record, enhancing confidence in the company's strategic direction.
Product Development
ArriVent Biopharma is leading the development of a chemo-sparing oral EGFR TKI treatment for NSCLC with promising safety compared to current standards.
Stock Performance
ArriVent BioPharma, Inc. is up 45% in the last 2 months leading into the Ph 1b EGFR PACC mut NSCLC data.
Negative Factors
Competitive Landscape
Confusion around PACC mutations vs atypical EGFR mutations is a concern, especially relevant to understanding the potential label and whether physicians will be differentiating atypical vs PACC specific.
Market Confusion
There is confusion around PACC mutations versus atypical EGFR mutations, which is relevant to understanding the potential label and differentiation by physicians.
ArriVent BioPharma, Inc. (AVBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$838.21M
Dividend YieldN/A
Average Volume (3M)260.59K
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue GrowthN/A
EPS Growth-15.71%
CountryUS
Employees52
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.90
Shares Outstanding34,212,563
10 Day Avg. Volume400,510
30 Day Avg. Volume260,591
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)16.25
Price to Sales (P/S)0.00
P/FCF Ratio-53.22
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.78
Forecast
1Y Price Target
$39.83Price Target Upside62.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
ArriVent BioPharma, Inc. Business Overview & Revenue Model
Company DescriptionArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
How the Company Makes MoneyArriVent BioPharma, Inc. generates revenue through the development and commercialization of its proprietary drug candidates. The company's key revenue streams include licensing agreements with other pharmaceutical companies, sales of its approved therapies, and potential milestone payments and royalties from its strategic partnerships. These partnerships often involve collaborations for research and development, as well as co-commercialization opportunities, allowing ArriVent to expand its market reach and accelerate product development.
ArriVent BioPharma, Inc. Financial Statement Overview
Summary
ArriVent BioPharma, Inc. is in the growth phase typical for biotech firms, with no revenue but substantial R&D investments. The balance sheet shows strong equity and low leverage, while cash flows indicate a need for external financing to support operations.Income Statement
ArriVent BioPharma, Inc. showed no revenue or gross profit, with increasing net losses over the years. EBIT and EBITDA margins are negative, reflecting high operating losses, typical for a biotech company in the development phase.10
Very Negative
Balance Sheet
The company's balance sheet shows strong equity and low debt levels, with a low debt-to-equity ratio. Stockholders' equity has increased over the years, indicating good financial stability despite operating losses.50
Neutral
Cash Flow
Cash flow analysis reveals negative free cash flow due to high operating expenses, typical for biotech firms focusing on R&D. However, the company has been successful in raising financing, maintaining substantial cash reserves.40
Negative
| Breakdown | ||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
| -73.63M | -94.31M | -74.59M | -36.91M | -8.70M | EBITDA |
| -73.63M | -80.49M | -74.59M | -36.91M | -51.61M | Net Income Common Stockholders |
| -127.46M | -80.49M | -69.33M | -36.91M | -51.61M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 176.08M | 218.86M | 150.39M | 163.37M | 37.28M | Total Assets |
| 215.50M | 274.94M | 163.10M | 182.83M | 43.04M | Total Debt |
| 138.00K | 176.00K | 317.00K | 139.00K | 0.00 | Net Debt |
| -49.73M | -74.12M | -150.07M | -163.23M | -37.28M | Total Liabilities |
| 12.95M | 17.29M | 11.80M | 8.37M | 1.82M | Stockholders Equity |
| 202.54M | 257.65M | 151.30M | 174.46M | 41.22M |
| Cash Flow | Free Cash Flow | |||
| -119.59M | -70.21M | -55.84M | -43.63M | -12.59M | Operating Cash Flow |
| -119.59M | -70.21M | -55.84M | -43.63M | -12.59M | Investing Cash Flow |
| -155.64M | -192.47M | 0.00 | 0.00 | -40.00M | Financing Cash Flow |
| 7.71M | 186.58M | 42.86M | 169.72M | 89.87M |
ArriVent BioPharma, Inc. Technical Analysis
Positive
24.50
Price Trends
20.07
Positive
22.13
Positive
24.82
Negative
Market Momentum
1.01
Negative
61.83
Neutral
82.55
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVBP, the sentiment is Positive. The current price of 24.5 is above the 20-day moving average (MA) of 21.41, above the 50-day MA of 20.07, and below the 200-day MA of 24.82, indicating a neutral trend. The MACD of 1.01 indicates Negative momentum. The RSI at 61.83 is Neutral, neither overbought nor oversold. The STOCH value of 82.55 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVBP.
ArriVent BioPharma, Inc. Risk Analysis
ArriVent BioPharma, Inc. disclosed 91 risk factors in its most recent earnings report. ArriVent BioPharma, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, the section of this Annual Report titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and related notes appearing elsewhere in this Annual Report, before investing in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business, operating results and prospects could be materially harmed. In that event, the price of our common stock could decline, and you could lose part or all of your investment. This Annual Report also contains forward-looking statements that involve risks and uncertainties. See "Special Note Regarding Forward-Looking Statements." Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below. Q4, 2024
2.
Firmonertinib has been granted Breakthrough Therapy Designation for the treatment of first-line patients with locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations from the FDA and we may seek Breakthrough Therapy Designation for other product candidates in the future. Even if we apply for Breakthrough Therapy Designation in the future, we might not receive such designation, and even if received, such designation may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval. Q4, 2024
3.
Even if we receive regulatory approval for firmonertinib or any Q4, 2024
ArriVent BioPharma, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (57)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $4.90B | 18.92 | -17.01% | 7.26% | 13.61% | -24.47% | |
54 Neutral | $933.92M | ― | -63.56% | ― | 270.02% | 32.69% | |
52 Neutral | $693.20M | ― | -33.48% | ― | -25.88% | -29.16% | |
50 Neutral | $679.92M | ― | -79.02% | ― | -50.69% | 8.01% | |
45 Neutral | $860.87M | ― | -119.66% | ― | ― | -551.08% | |
40 Underperform | $340.45M | ― | -60.45% | ― | ― | 6.99% | |
39 Underperform | $838.21M | ― | -49.00% | ― | ― | -15.71% |
* General Sector Average
Performance Comparison
AVBP
ArriVent BioPharma, Inc.
23.28
4.62
24.76%
ABUS
Arbutus Biopharma
3.50
0.25
7.69%
XNCR
Xencor
9.52
-12.50
-56.77%
RCKT
Rocket Pharmaceuticals
3.03
-19.70
-86.67%
NUVB
Nuvation Bio
2.20
-0.72
-24.66%
PRAX
Praxis Precision Medicines
44.60
3.51
8.54%
ArriVent BioPharma, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
ArriVent BioPharma Appoints Merdad Parsey as New Director
Neutral
Apr 28, 2025
On April 23, 2025, Carl L. Gordon announced he would not seek re-election to the board of ArriVent BioPharma, Inc. at the upcoming annual meeting. Subsequently, the board expanded from seven to eight members, appointing Merdad Parsey, M.D., Ph.D., as a new director effective April 28, 2025. Dr. Parsey, with extensive experience in the biopharmaceutical industry, including roles at Gilead Sciences and Genentech, is expected to contribute significantly to ArriVent’s strategic growth and development of its cancer treatment portfolio. The board also reclassified directors Zhengbin Yao and Kristine Peterson to balance membership among its classes, maintaining continuity in their roles.
Spark’s Take on AVBP Stock
According to Spark, TipRanks’ AI Analyst, AVBP is a Underperform.
The overall score reflects the high-risk, high-reward nature of an early-stage biotechnology company like ArriVent BioPharma. While the company shows strong balance sheet stability and strategic pipeline expansion, the lack of current revenue, negative cash flows, and recent downward price trends weigh heavily on the score. Investors should consider the potential long-term benefits of the oncology pipeline expansion balanced against the typical risks associated with biotech investments.
To see Spark’s full report on AVBP stock, click here.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.